Roflumilast Cream for Eczema
AM
Overseen ByArcutis Medical Information Arcutis Biotherapeutics, Inc.
Age: < 18
Sex: Any
Trial Phase: Phase 2
Sponsor: Arcutis Biotherapeutics, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Trial Summary
What is the purpose of this trial?
This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema).
Eligibility Criteria
This trial is for infants aged 3 months to less than 2 years who have been diagnosed with atopic dermatitis, also known as eczema. The key requirement is that they must be able to apply the cream once daily for four weeks.Inclusion Criteria
Informed consent of a parent(s) or legal guardian(s), as required by local laws
In good health as judged by the Investigator
I am between 3 months and 2 years old.
See 3 more
Exclusion Criteria
Subjects with any serious medical condition, clinically significant vital signs, or physical examination abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator
Parent(s)/legal guardian(s) who are unable to communicate, read, or understand the local language. Subjects who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation
Subjects who are family members of the clinical study staff or sponsor
See 3 more
Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Treatment
Participants receive ARQ-151 cream 0.05% applied once daily for 4 weeks
4 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
4 weeks
Treatment Details
Interventions
- ARQ-151 cream 0.05%
Trial Overview The study tests the safety of a cream called ARQ-151 at a concentration of 0.05%. Infants in the trial will use this cream on their skin once every day for a month to see how well they tolerate it.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: ARQ-151 roflumilast cream 0.05% (open label)Experimental Treatment1 Intervention
This single study arm is open label in which ARQ-151 cream 0.05% is applied daily for 4 weeks.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Arcutis Biotherapeutics, Inc.
Lead Sponsor
Trials
22
Recruited
7,600+
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.